Biography and Research Information
OverviewAI-generated summary
Cesar Gentille's research focuses on the clinical outcomes and treatment strategies for patients with hematologic malignancies, particularly multiple myeloma and lymphoma. His work investigates the efficacy of novel immunotherapies, including CAR-T cell therapy and bispecific T-cell engagers, in relapsed or refractory disease settings. Gentille has published studies examining opportunistic infections in patients undergoing daratumumab regimens for multiple myeloma and the association between specific immune responses, such as cytokine release syndrome, and adverse cardiac events following CAR-T therapy. He also explores outcomes for treatments like mogamulizumab in Sézary syndrome. Gentille collaborates with researchers at the University of Arkansas for Medical Sciences, including Toshali Pandey, Curran Henson, Grant M. Spears, and Bhavesh Mohan Lal, with whom he has co-authored publications.
Metrics
- h-index: 1
- Publications: 8
- Citations: 12
Selected Publications
-
Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report (2026)
-
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)
-
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome (2025)
Collaboration Network
Top Collaborators
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
Similar Researchers
Based on overlapping research topics